New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 24, 2013
12:00 EDTORMPOramed Pharmaceuticals rises 32.9%
Oramed Pharmaceuticals is up 32.9%, or $3.85, to $15.56
News For ORMP From The Last 14 Days
Check below for free stories on ORMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
14:33 EDTORMPOramed says ORMD-0801 appeared safe and well-tolerated in phase IIa trial
Oramed Pharmaceuticals announced detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2 diabetes patients. The preliminary results of this trial were originally announced on January 30. The results showed that ORMD-0801 oral insulin appeared to be safe and well-tolerated for the dosing regimen considered in this study. No hypoglycemic events occurred at any point in any treatment group and no treatment related adverse events were observed. Although the study was not powered to show statistical significance, there were trends observed showing pattern of well-defined and short-term increases in plasma insulin and decreases in blood glucose. Chief Scientific Officer Dr. Miriam Kidron stated, "We are very pleased with the outcome of this study, which showed ORMD-0801 to be safe and well-tolerated. Importantly, the decreases in blood glucose we observed were not associated with any hypoglycemic events. We look forward to moving ahead with our planned U.S. Phase IIb trial in individuals with type 2 diabetes which will investigate ORMD-0801 over a longer treatment period and which will have statistical power to give us greater insight into the drug's efficacy."
April 10, 2014
08:11 EDTORMPOramed granted patent in Hong Kong for oral administration of insulin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use